Form 4 for CTSO Cytosorbents Corp
Accepted 2026-09-16 17:30:30 ET · period of report 2026-09-15 · accession 0001104659-26-108326 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-16 17:30 | 2026-09-15 | CTSO | Chan Phillip P. | CEO, Dir | P - Purchase | $6.00 | +3,774 | 101.0K | +4% | +$22.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | P | A | 3,774 | $6.00 | 100,996 | D | — | — | (F1) This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. (F2) Includes: (i) the following restricted stock units ("RSUs") that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 515 RSUs granted on March 15, 2018, (b) 935 RSUs granted on February 24, 2017, (c) 2,850 RSUs granted on June 7, 2016 and (d) 6,500 RSUs granted on April 8, 2015; (F3) (continued from footnote 2) (ii) 2,640 RSUs of 5,280 granted on August 8, 2025, which vest in equal parts at the first and second year anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and (iii) 83,782 shares of Common Stock owned by the Reporting Person. (F4) Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026. |